Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 provides no operating results; substantive earnings information likely appears in an incorporated exhibit.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 provides no operating results; substantive earnings information likely appears in an incorporated exhibit
- Disclosure liability protections indicate the filing content is furnished, not filed under the Securities Act or Exchange Act
Item EX-99.1 · Exhibit EX-99.1
- Q2 net income $123.2M, or $1.09 basic EPS, driven primarily by $178.2M net PRV-sale gain
- Cash, equivalents and investments $283.7M, up from $188.9M at December 31, 2025, with runway into Q2 2028
- RP-A501 safety observation completed for all three initial patients without significant concerns, supporting FDA discussions on additional dosing
- KRESLADI commercial availability and patient onboarding targeted for Q4 2026, following FDA approval and $180M gross PRV monetization
- R&D fell to $29.5M from $42.7M and G&A to $17.4M from $25.0M, reflecting reduced headcount and lower development spending
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.